The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Intratumoral injection of Clostridium novyi -NT spores induces antitumor responses
Open accessAbstract
Clostridium novyi -NT targets aberrant tumor physiology and can produce a precise, robust, and reproducible antitumor response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with intratumoral or intravenous injection often leading to ~10,000-fold accumulation in tumors relative to matched liver, spleen, and lung tissues (152, 153).”
From The microbiome and human cancer (2021) · cites this paper as [153]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
Isaacson, P. G., Dogan, A., Price, S. K., & Spencer, J. (1989) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198912000-00004 · Cited by 1,915
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T.-L., Shih, I.-M., Mao, T.-L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,219 · cited 1×
“Potential somatic mutations were filtered and visually inspected as described previously (38).”
MethodSelf-citationCOLEY, W. B. (1991) · PubMed · Cited by 965
Engineering the perfect (bacterial) cancer therapy
Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905 · cited 1×
“More recent work involved attenuated strains of Salmonella typhimurium and others (13, 14).”
BackgroundCanine Cutaneous Mast Cell Tumor: Morphologic Grading and Survival Time in 83 Dogs
Patnaik, A. K., Ehler, W. J., & MacEwen, E. G. (1984) · Veterinary Pathology · doi:10.1177/030098588402100503 · Cited by 843
Comparing antibody and small-molecule therapies for cancer
Imai, K., & Takaoka, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1913 · Cited by 792
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
Barretina, J., Taylor, B. S., Banerji, S., Ramos, A. H., Lagos-Quintana, M., DeCarolis, P. L., Shah, K., Socci, N. D., Weir, B. A., Ho, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.619 · Cited by 735
Developmental and Pathological Angiogenesis
Chung, A. S., & Ferrara, N. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154002 · Cited by 722
Translation of new cancer treatments from pet dogs to humans
Paoloni, M., & Khanna, C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2273 · Cited by 668 · cited 2×
“In companion dogs, however, clinically used therapeutic agents induce similar toxicities and effects as found in people (23).”
BackgroundImaging hypoxia to improve radiotherapy outcome
Horsman, M. R., Mortensen, L. S., Petersen, J. B., Busk, M., & Overgaard, J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.171 · Cited by 614 · cited 1×
“Additionally, radiotherapy fails to kill hypoxic cells because oxygen is a required effector of radiation-induced cell death (9).”
BackgroundToso, J. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.142 · Cited by 614
Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors
Chmielecki, J., Crago, A. M., Rosenberg, M., O'Connor, R., Walker, S. R., Ambrogio, L., Auclair, D., McKenna, A., Heinrich, M. C., Frank, D. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2522 · Cited by 606
Combination bacteriolytic therapy for the treatment of experimental tumors
Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W., & Vogelstein, B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251543698 · Cited by 563 · cited 4×
“novyi-NT spores, produced as previously described (18, 37), were stereotactically injected into the intracranial tumor using the same coordinates as described above.”
BackgroundMethodInfluentialSelf-citationSpontaneously Occurring Tumors of Companion Animals as Models for Human Cancer
Vail, D. M., & Macewen, E. G. (2000) · Cancer Investigation · doi:10.3109/07357900009012210 · Cited by 528
A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers
Lee, R. S., Stewart, C., Carter, S. L., Ambrogio, L., Cibulskis, K., Sougnez, C., Lawrence, M. S., Auclair, D., Mora, J., Golub, T. R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64400 · Cited by 428 · cited 1×
“61/Mb) (table S1), similar to estimates of the mutation rate in human pediatric rhabdoid tumors (26) and other soft tissue sarcomas (27).”
BackgroundColey, W. B. (1910) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591571000301601 · Cited by 423
Nemunaitis, J., Cunningham, C., Senzer, N., Kuhn, J., Cramm, J., Litz, C., Cavagnolo, R., Cahill, A., Clairmont, C., & Sznol, M. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700634 · Cited by 341 · cited 1×
“typhimurium therapy, genetically modified strains incorporating cytosine deaminase, which converts systemically administered 5-flurocytosine to 5-flurouracil, have been developed and evaluated in patients (17).”
BackgroundBacteriolytic therapy can generate a potent immune response against experimental tumors
Agrawal, N., Bettegowda, C., Cheong, I., Geschwind, J.-F., Drake, C. G., Hipkiss, E. L., Tatsumi, M., Dang, L. H., Diaz, L. A., Pomper, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406242101 · Cited by 304 · cited 4×
“novyi-NT has been shown to induce a potent antitumor immune response (20), we sought to determine whether canine soft tumor sarcomas were genetically similar to those of humans and, as such, would be a suitable comparative model.”
BackgroundInfluentialSelf-citationPrognostic Factors for Cutaneous and Subcutaneous Soft Tissue Sarcomas in Dogs
Dennis, M. M., McSporran, K. D., Bacon, N. J., Schulman, F. Y., Foster, R. A., & Powers, B. E. (2011) · Veterinary Pathology · doi:10.1177/0300985810388820 · Cited by 303
(2004) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5810.2004.0053b.x · Cited by 240
Smedley, R. C., Spangler, W. L., Esplin, D. G., Kitchell, B. E., Bergman, P. J., Ho, H.-Y., Bergin, I. L., & Kiupel, M. (2011) · Veterinary Pathology · doi:10.1177/0300985810390717 · Cited by 206
Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
Bai, R.-Y., Staedtke, V., Aprhys, C. M., Gallia, G. L., & Riggins, G. J. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor077 · Cited by 201 · cited 1×
“F98 glioma cells (2 × 10(4)) transfected with a luciferase construct via lentivirus were stereotactically implanted through a burr hole into the right frontal lobe located 3 mm lateral and 2 mm anterior to the bregma, as described before (36).”
MethodSelf-citationExomics and immunogenics: Bridging mutational load and immune checkpoints efficacy
Champiat, S., Ferté, C., Lebel-Binay, S., Eggermont, A., & Soria, J. C. (2014) · OncoImmunology · doi:10.4161/onci.27817 · Cited by 192
Scaling rules for diffusive drug delivery in tumor and normal tissues
Baish, J. W., Stylianopoulos, T., Lanning, R. M., Kamoun, W. S., Fukumura, D., Munn, L. L., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018154108 · Cited by 182
Thamm, D. H., Kurzman, I. D., King, I., Li, Z., Sznol, M., Dubielzig, R. R., Vail, D. M., & MacEwen, E. G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2510 · Cited by 174
Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria
Bettegowda, C., Dang, L. H., Abrams, R., Huso, D. L., Dillehay, L., Cheong, I., Agrawal, N., Borzillary, S., McCaffery, J. M., Watson, E. L., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2036598100 · Cited by 172
Self-citationA Bacterial Protein Enhances the Release and Efficacy of Liposomal Cancer Drugs
Cheong, I., Huang, X., Bettegowda, C., Diaz, L. A., Kinzler, K. W., Zhou, S., & Vogelstein, B. (2006) · Science · doi:10.1126/science.1130651 · Cited by 168 · cited 1×
“novyi-NT spores, at least when administered systemically, are markedly enhanced by combination with carefully chosen chemotherapeutic agents or radiation therapy (19, 34, 35).”
BackgroundSelf-citationThe genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT
Bettegowda, C., Huang, X., Lin, J., Cheong, I., Kohli, M., Szabo, S. A., Zhang, X., Diaz, L. A., Velculescu, V. E., Parmigiani, G., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1256 · Cited by 162 · cited 2×
“novyi-NT spores, produced as previously described (18, 37), were stereotactically injected into the intracranial tumor using the same coordinates as described above.”
MethodSelf-citationBacterial targeted tumour therapy-dawn of a new era
Wei, M. Q., Mengesha, A., Good, D., & Anné, J. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.10.034 · Cited by 159
Pharmacologic and Toxicologic Evaluation of C. novyi-NT Spores
Diaz, L. A., Cheong, I., Foss, C. A., Zhang, X., Peters, B. A., Agrawal, N., Bettegowda, C., Karim, B. O., Liu, G., Khan, K., et al. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfi316 · Cited by 117 · cited 3×
“One problem encountered with systemic injection of spores is the small proportion of spores that actually are delivered to tumors (22).”
BackgroundInfluentialSelf-citationExomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas
Joseph, C. G., Hwang, H., Jiao, Y., Wood, L. D., Kinde, I., Wu, J., Mandahl, N., Luo, J., Hruban, R. H., Diaz, L. A., et al. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22114 · Cited by 114 · cited 2×
“Mutations in ATP7B were also found in a human liposarcoma (27).”
BackgroundSelf-citationHistologic Grading of Canine Mast Cell Tumor
Sabattini, S., Scarpa, F., Berlato, D., & Bettini, G. (2014) · Veterinary Pathology · doi:10.1177/0300985814521638 · Cited by 101
Targeting Vascular and Avascular Compartments of Tumors withC. novyi-NTand Anti-microtubule Agents
Dang, L. H., Bettegowda, C., Agrawal, N., Cheong, I., Huso, D. L., Frost, P., Loganzo, F., Greenberger, L. M., Barkóczy, J., Pettit, G. R., et al. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.3.704 · Cited by 97
Self-citationEvaluation of Clostridium novyi–NT spores in dogs with naturally occurring tumors
Krick, E., Sørenmo, K. U., Rankin, S. C., Cheong, I., Kobrin, B. J., Thornton, K. A., Kinzler, K. W., Vogelstein, B., Zhou, S., & Diaz, L. A. (2011) · American Journal of Veterinary Research · doi:10.2460/ajvr.73.1.112 · Cited by 71 · cited 1×
“novyi-NT spores were evaluated in spontaneously occurring canine tumors (21).”
BackgroundSelf-citationMethods for the development of tumor-targeting bacteria
Hoffman, R. M., & Zhao, M. D. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.916270 · Cited by 46
Zhang, G., & Yang, Y. (2008) · Journal of Combinatorial Optimization · doi:10.1007/s10878-008-9199-0 · Cited by 32
Uveal Spindle Cell Tumor of Blue-Eyed Dogs: An Immunohistochemical Study
Zarfoss, M. K., Klauss, G., Newkirk, K. M., Kiupel, M., Jones, Y., Colitz, C. M. H., & Dubielzig, R. R. (2007) · Veterinary Pathology · doi:10.1354/vp.44-3-276 · Cited by 32
ISOLATION OF TOXIGENIC STRAINS OF CLOSTRIDIUM NOVYI FROM SOIL
Nishida, S., & Nakagawara, G. (1964) · Journal of Bacteriology · doi:10.1128/jb.88.6.1636-1640.1964 · Cited by 29
Boynton, F. D. D., Teixeira, L. B. C., Galle, L. E., Green, N., & Dubielzig, R. R. (2014) · Veterinary Pathology · doi:10.1177/0300985814522811 · Cited by 11
Research works printed but not linked: 1
- 10.1200/JCO.2002.20.1.142 · DOI · Paper page
Cited by
Garrett, W. S. (2015) · Science · doi:10.1126/science.aaa4972 · Cited by 1,404
The microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
“5B), with intratumoral or intravenous injection often leading to ~10,000-fold accumulation in tumors relative to matched liver, spleen, and lung tissues (152, 153).”
BackgroundTumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Self-citationThe microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aar6918 · Cited by 777
Zheng, J. H., Nguyen, V. H., Jiang, S.-N., Park, S.-H., Tan, W., Hong, S. H., Shin, M. G., Chung, I.-J., Hong, Y., Bom, H.-S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9537 · Cited by 588
Metadata
- Authors
- Roberts, N. J., Zhang, L., Janku, F., Collins, A., Bai, R.-Y., Staedtke, V., Rusk, A. W., Tung, D., Miller, M., Roix, J., Khanna, K. V., Murthy, R., Benjamin, R. S., Helgason, T., Szvalb, A. D., Bird, J. E., Roy-Chowdhuri, S., Zhang, H. H., Qiao, Y., Karim, B., McDaniel, J., Elpiner, A., Sahora, A., Lachowicz, J., Phillips, B., Turner, A., Klein, M. K., Post, G., Diaz, L. A., Riggins, G. J., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., Bettegowda, C., Huso, D. L., Varterasian, M., Saha, S., & Zhou, S.
- Affiliations
- Howard Hughes Medical Institute (US)
- BioMed Valley Discoveries Inc., 4520 Main Street, Kansas City, MO 64111, USA.
- Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Johns Hopkins University (US)
- Animal Clinical Investigation LLC, 4926 Wisconsin Avenue, NW Washington, DC 20016, USA.
- The University of Texas MD Anderson Cancer Center (US)
- Department of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
- The Veterinary Cancer Center, 129 Glover Avenue, Norwalk, CT 06850, USA.
- VCA Great Lakes Veterinary Specialists, 5035 Richmond Road, Bedford Heights, OH 44146, USA.
- The Oncology Service, Friendship Hospital for Animals, 4105 Brandywine Street, NW, Washington, DC 20016, USA.
- BluePearl Veterinary Partners, 410 West 55th Street, New York, NY 10019, USA.
- Veterinary Specialty Hospital of San Diego, 10435 Sorrento Valley Road, San Diego, CA 92121, USA.
- Veterinary Cancer Group of Los Angeles at City of Angels Veterinary Specialty Center, 9599 Jefferson Boulevard, Culver City, CA 90232, USA.
- Southern Arizona Veterinary Specialty and Emergency Center, 141 East Fort Lowell, Tucson, AZ 85705, USA.
- Corresponding author
- Roberts, Nicholas J.
- Zhang, Linping
- Collins, Amanda
- Bai, Ren-Yuan
- Staedtke, Verena
- Saha, Saurabh
- Zhou, Shibin
- ORCID
- Roberts, Nicholas J.
- Zhang, Linping
- Bai, Ren-Yuan
- Staedtke, Verena
- Tung, David
- Murthy, Ravi
- Benjamin, Robert S.
- Szvalb, Ariel D.
- Bird, Justin E.
- Qiao, Yuan
- Karim, Baktiar
- Post, Gerald
- Diaz, Luis A.
- Riggins, Gregory J.
- Papadopoulos, Nickolas
- Kinzler, Kenneth W.
- Vogelstein, Bert
- Bettegowda, Chetan
- Varterasian, Mary
- Saha, Saurabh
- Zhou, Shibin
- Venue
- Science Translational Medicine
- Published
- 2014-08-13
- Volume
- 6
- Issue
- 249
- Pages
- 249ra111-249ra111
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC4399712
- OpenAlex
- W2160952303
- Cited by
- 400
- References
- 49
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 43 · 2023: 39 · 2022: 56 · 2021: 37 · 2020: 34 · 2019: 27 · 2018: 20 · 2017: 29 · 2016: 29 · 2015: 25 · 2014: 7
- FWCI
- 25.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA129825, CA129825, P50CA062924, CA062924, P30CA006973)
- National Institute of Neurological Disorders and Stroke (R25NS065729)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- Clostridium novyi-NT, intratumoral injection, bacterial spores, antitumor immunity, translational cancer models, hypoxic tumor cells, tumor cell lysis, leiomyosarcoma, bacterial therapy, pet dogs
- MeSH terms
- Animals, Clostridium, Dogs, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Necrosis, Neoplasms, Sarcoma, Spores, Bacterial, Tomography, X-Ray Computed, Reproducibility of Results, Injections, Intralesional, Treatment Outcome, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.